Table 3.
Infliximab discontinuation | Retransitioned due to objective markers (n = 6) | Retransitioned due to symptoms only (n = 38) |
---|---|---|
Infliximab continuation | 2 (33.3%) | 29 (76.3%) |
Overall infliximab discontinuation | 4 (66.7%) | 9 (23.7%) |
Infliximab discontinuation | Retransitioned due to objective markers (n = 6) | Retransitioned due to symptoms only (n = 38) |
---|---|---|
Infliximab continuation | 2 (33.3%) | 29 (76.3%) |
Overall infliximab discontinuation | 4 (66.7%) | 9 (23.7%) |